Pfizer Joins Obesity Drug Race With $5B Metsera Purchase

Pfizer will pay $4.9 billion for the obesity startup Metsera in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications. Bloomberg health reporter Madison Muller joins Bloomberg Open Interest to talk about the implications. (Source: Bloomberg)...

Redirecting to full article...